Emcure Pharmaceuticals Fair Value

Emcure Pharmaceuticals (EMCURE) average fair value is ₹456.37 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹1638.0 (-72.14%), fair value range ₹218.41–₹785.48. For live price and a broader fundamental view, visit EMCURE stock live price.

Average Fair Value
₹456.37
Current Market Price: ₹1638.0
-72.14% Price Difference

Fair Value Analysis Export

EMCURE Fair Value vs Current Price — Valuation Summary

EMCURE average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore Emcure Pharmaceuticals intrinsic worth to estimate fundamental worth using multiple valuation models.

Average Fair Value
₹456.37
Current Market Price
₹1638.0
Price Difference
₹-1181.63
Percentage Difference
-72.14%
Fair Value Range
₹218.41 - ₹785.48
Methods Used
6
Analysis based on 6 valuation methods: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF)

P/E Based Valuation

Current EPS ₹12.85
Sector Avg P/E 15.99
Historical Avg P/E N/A
Average Fair Value
₹218.41

P/B Based Valuation

Book Value/Share ₹244.32
Sector Avg P/B 4.93
Historical Avg P/B N/A
Average Fair Value
₹785.48

Price-to-Sales Valuation

Revenue/Share ₹122.72
Sector Avg P/S 4.0
Fair Value
₹490.89

Asset-Based Valuation

Book Value/Share ₹244.32
Liquidation Value/Share ₹303.32
Fair Value
₹244.32

Benjamin Graham Number

Current EPS ₹12.85
Book Value/Share ₹244.32
Graham Multiplier 22.5
Current P/E 33.81
Graham Criteria 0/3
Graham Number
₹265.78

Discounted Cash Flow (DCF)

Current FCF ₹852.0 Cr
FCF Growth Rate 4.89%
Discount Rate 10.0%
Terminal Growth 3.0%
Enterprise Value ₹13582.35 Cr
DCF Fair Value
₹733.33

EMCURE Fair Value Analysis — Data Sources & Coverage

Emcure Pharmaceuticals financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. Examine EMCURE quarterly results for recent quarterly revenue, profit and EPS trends.

Methods Used
6
Data Year
2025
Sector
Healthcare

Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.

Data Currency: Financial data is from the previous year (2025).

EMCURE vs Healthcare Sector Peers — P/E, P/B & Market Cap

Emcure Pharmaceuticals P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.

Company Symbol P/E Ratio P/B Ratio Market Cap (₹ Cr)
Jeena Sikho Lifecare JSLL 41.98 23.98 ₹8,202
Accretion Pharmaceuticals ACCPL 14.17 2.14 ₹100
Par Drugs & Chemical PAR 8.21 1.07 ₹114
Murae Organisor MURAE 2.86 0.2 ₹41
Acutaas Chemicals ACUTAAS 67.89 13.68 ₹19,737

Important Disclaimer

This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.

This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.

Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.